Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026)

K J Armour, R J van 't Hof, K E Armour, A C Torbergsen, P Del Soldato, S H Ralston

Research output: Contribution to journalArticlepeer-review

Abstract

Inhibitors of prostaglandin production, such as nonsteroidal antiinflammatory drugs (NSAIDs), and pharmacologic nitric oxide (NO) donors, such as organic nitrates, have been suggested to protect against bone loss in both humans and experimental animals. Recently, a new class of nitrosylated NSAID (known as NO-NSAIDs) has been developed, which combines the properties of a NO donor with those of a cyclooxygenase (COX) inhibitor. This study investigated the effects of one of these compounds, flurbiprofen nitroxybutylester (HCT1026), on bone metabolism in vitro and in vivo.
Original languageEnglish
Pages (from-to)2185-92
Number of pages8
JournalArthritis and rheumatism
Volume44
Issue number9
Publication statusPublished - 2001

Fingerprint

Dive into the research topics of 'Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026)'. Together they form a unique fingerprint.

Cite this